ImmuneBridge
Latest round
- Seed
Last raised
- Apr 2023
Total raised
- $22M
Investors
- 5
About ImmuneBridge
a. ImmuneBridge operates as a biotech company that develops allogeneic cellular immunotherapies for hematologic malignancies and solid tumors. In April 2023, ImmuneBridge Inc. The company offers a cellular discovery platform that uses cord blood for the purpose of screening and selecting cancer-fighting cells. ImmuneBridge develops allogeneic, off-the-shelf cellular immunotherapies, starting with natural killer (NK) cell-based immunotherapies, which originate from CD34+ hematopoietic stem cells (HSCs).
Who invested in ImmuneBridge
5 investors across 3 rounds
See all investors in ImmuneBridge
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ImmuneBridge
Who invested in ImmuneBridge?
ImmuneBridge has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ImmuneBridge raised?
ImmuneBridge has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did ImmuneBridge last raise money?
ImmuneBridge's most recent round on record is a Seed, in Apr 2023.
What does ImmuneBridge do?
ImmuneBridge is a biotechnology company.
Where is ImmuneBridge headquartered?
ImmuneBridge is headquartered in San Francisco, US.
Which VCs invest in companies like ImmuneBridge?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ImmuneBridge's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like ImmuneBridge? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.